Equities analysts expect that Heron Therapeutics Inc (NASDAQ:HRTX) will post sales of $31.91 million for the current quarter, according to Zacks. Four analysts have issued estimates for Heron Therapeutics’ earnings, with the highest sales estimate coming in at $34.60 million and the lowest estimate coming in at $26.80 million. Heron Therapeutics posted sales of $17.28 million in the same quarter last year, which suggests a positive year-over-year growth rate of 84.7%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, August 14th.
On average, analysts expect that Heron Therapeutics will report full year sales of $119.99 million for the current year, with estimates ranging from $114.40 million to $124.85 million. For the next year, analysts anticipate that the business will post sales of $211.55 million, with estimates ranging from $185.00 million to $245.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). The business had revenue of $31.60 million for the quarter, compared to analysts’ expectations of $28.04 million. Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The business’s quarterly revenue was up 172.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.09) earnings per share.
Heron Therapeutics stock opened at $18.06 on Friday. The company has a market cap of $1.45 billion, a PE ratio of -7.40 and a beta of 1.45. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06. Heron Therapeutics has a 52 week low of $16.20 and a 52 week high of $42.90.
In other news, Director Waage Christian acquired 1,400 shares of Heron Therapeutics stock in a transaction that occurred on Wednesday, May 15th. The shares were purchased at an average cost of $18.04 per share, for a total transaction of $25,256.00. Following the completion of the purchase, the director now directly owns 1,400 shares of the company’s stock, valued at approximately $25,256. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 12.56% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new position in Heron Therapeutics during the fourth quarter worth $13,679,000. Boston Advisors LLC lifted its stake in Heron Therapeutics by 443.9% in the first quarter. Boston Advisors LLC now owns 134,559 shares of the biotechnology company’s stock valued at $3,288,000 after buying an additional 109,819 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its stake in Heron Therapeutics by 144.6% in the fourth quarter. Los Angeles Capital Management & Equity Research Inc. now owns 19,690 shares of the biotechnology company’s stock valued at $511,000 after buying an additional 11,640 shares during the last quarter. Legal & General Group Plc lifted its stake in Heron Therapeutics by 6.5% in the fourth quarter. Legal & General Group Plc now owns 27,564 shares of the biotechnology company’s stock valued at $716,000 after buying an additional 1,679 shares during the last quarter. Finally, Congress Park Capital LLC lifted its stake in Heron Therapeutics by 32.2% in the fourth quarter. Congress Park Capital LLC now owns 46,575 shares of the biotechnology company’s stock valued at $1,208,000 after buying an additional 11,350 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More: What are the benefits of a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.